Biogen Idec Inc. 10-Q Summary: Period Ended June 30, 2007
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for Biogen Idec Inc., an international biotechnology company focused on oncology, neurology, and immunology. The reporting period covers the three and six months ended June 30, 2007. The company's primary products include AVONEX, RITUXAN, TYSABRI, FUMADERM, and ZEVALIN. The period was marked by the re-launch of TYSABRI following a 2005 suspension and the initiation of a significant share repurchase tender offer.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2007) | Value (in millions) |
|---|---|
| Total Revenues | $1,489.1 |
| Net Income | $317.6 |
| Diluted Earnings Per Share | $0.92 |
| Operating Cash Flow | $464.3 |
| Cash and Cash Equivalents (End of Period) | $1,611.6 |
| Total Debt (Notes Payable) | $63.2 |
| Working Capital | $(770.9) |
Note: Working capital is negative primarily due to the classification of the $2,990 million tender offer obligation as a current liability.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 17.1% to $1,489.1 million from $1,271.2 million in the prior year period. This was driven by price increases and the re-launch of TYSABRI.
- Profitability Turnaround: The company reported net income of $317.6 million, a significant improvement from a net loss of $47.6 million in the same period in 2006. The prior year loss was heavily impacted by a $330.5 million charge for acquired in-process research and development (IPR&D).
- Expense Increases: Research and development expenses rose 33.0% to $409.6 million due to increased clinical trial activity. Selling, general, and administrative expenses increased 20.6% to $391.7 million, largely to support TYSABRI and AVONEX sales.
- Amortization: Amortization of intangible assets decreased 17.8% to $120.9 million due to a change in the estimate of economic consumption for core technology.
Guidance, Outlook, and Risks
- Tender Offer: In June 2007, the company completed a tender offer to repurchase 56.4 million shares at $53.00 per share for a total of approximately $2,990 million. This was funded by existing cash and a new $1.5 billion term loan facility.
- Acquisitions and Partnerships: The company acquired Syntonix Pharmaceuticals for $44.4 million (with potential milestones up to $124.4 million) to expand its hemophilia pipeline. Additionally, a joint development agreement with Cardiokine, Inc. was announced for a heart failure compound, involving a $50 million upfront payment.
- Manufacturing: Significant capital is being committed to a large-scale biologic manufacturing facility in Hillerod, Denmark. As of June 30, 2007, approximately $278 million was committed to the first phase and $188.7 million to the second phase.
- Risks: Key risks include dependence on AVONEX and RITUXAN (94% of 2006 revenue), the market acceptance of TYSABRI given safety warnings, potential litigation regarding product liability and marketing practices, and the impact of new anti-CD20 products on profit-sharing with Genentech.
Investor Verification Checklist
- Tender Offer Funding: Verify the terms and repayment schedule of the $1.5 billion term loan used to fund the share repurchase.
- TYSABRI Sales Trajectory: Monitor quarterly sales data for TYSABRI to assess market acceptance and the impact of safety restrictions on growth.
- Manufacturing Capacity: Track the progress and cost overruns of the Hillerod, Denmark facility expansion, which is critical for future TYSABRI supply.
- Legal Proceedings: Review updates on the class action lawsuit regarding TYSABRI safety disclosures and the DOJ investigation into RITUXAN promotion.
- IPR&D Charges: Watch for future non-cash charges related to the Syntonix acquisition and other pipeline developments.